Considerations for the Use of Checkpoint Inhibitors in Gastroesophageal Cancers

Gain expert insight on the use of ICIs either as monotherapy or in combination with targeted agents when managing patients with gastric or GEJ cancer, as informed by recent data from the 2019 Gastrointestinal Cancers Symposium.

Steven Maron, MD Released: February 26, 2019

With widening use of immune checkpoint inhibitors in patients with gastroesophageal cancer, it is critical for clinicians to stay abreast of the unique adverse events associated with these agents

Axel Grothey, MD Released: March 22, 2019

Which of our patients with advanced gastric/GEJ cancers are most likely to benefit from later-line treatment with PD-1 inhibitors? Here’s my take on applying the latest evidence to the clinic.

Tanios Bekaii-Saab, MD, FACP Released: July 18, 2019